Rosetta Genomics Ltd. Deferred Tax Assets, Net of Valuation Allowance
Rosetta Genomics Ltd. had Deferred Tax Assets, Net of Valuation Allowance of $39.36 million as of 2016-12-31, per its 6-K filed 2017-10-10.
Discontinued › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2017-10-10
- 2016-12-31: Deferred Tax Assets, Net of Valuation Allowance $39.36M.
- 2015-12-31: Deferred Tax Assets, Net of Valuation Allowance $42.47M.
- 2014-12-31: Deferred Tax Assets, Net of Valuation Allowance $34.41M.
- 2013-12-31: Deferred Tax Assets, Net of Valuation Allowance $34.40M.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2016-12-31 | $39.36M 6-K · filed 2017-10-10 |
| 2015-12-31 | $42.47M 6-K · filed 2017-10-10 |
| 2014-12-31 | $34.41M 6-K · filed 2016-12-08 |
| 2013-12-31 | $34.40M 20-F · filed 2015-03-16 |
| 2012-12-31 | $27.67M 20-F · filed 2014-03-31 |
| 2011-12-31 | $22.66M 20-F · filed 2013-03-22 |